Haemonetics Corporation (HAE): Price and Financial Metrics
HAE Price/Volume Stats
Current price | $75.79 | 52-week high | $95.26 |
Prev. close | $74.82 | 52-week low | $70.74 |
Day low | $74.62 | Volume | 445,500 |
Day high | $76.13 | Avg. volume | 457,489 |
50-day MA | $77.75 | Dividend yield | N/A |
200-day MA | $85.03 | Market Cap | 3.85B |
HAE Stock Price Chart Interactive Chart >
HAE POWR Grades
- Quality is the dimension where HAE ranks best; there it ranks ahead of 86.61% of US stocks.
- HAE's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
- HAE ranks lowest in Momentum; there it ranks in the 4th percentile.
HAE Stock Summary
- HAE's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 121.71 -- higher than 77.5% of US-listed equities with positive expected earnings growth.
- HAEMONETICS CORP's stock had its IPO on May 10, 1991, making it an older stock than 84.19% of US equities in our set.
- The volatility of HAEMONETICS CORP's share price is greater than that of merely 1.64% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to HAEMONETICS CORP are CMCO, LXFR, MTRN, XRX, and XGN.
- Visit HAE's SEC page to see the company's official filings. To visit the company's web site, go to www.haemonetics.com.
HAE Valuation Summary
- HAE's price/sales ratio is 3.5; this is 16.67% lower than that of the median Healthcare stock.
- Over the past 243 months, HAE's price/earnings ratio has gone up 10.7.
Below are key valuation metrics over time for HAE.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
HAE | 2023-12-29 | 3.5 | 4.9 | 33.8 | 28.4 |
HAE | 2023-12-28 | 3.6 | 4.9 | 34.4 | 28.8 |
HAE | 2023-12-27 | 3.6 | 4.9 | 34.4 | 28.8 |
HAE | 2023-12-26 | 3.6 | 4.9 | 34.3 | 28.7 |
HAE | 2023-12-22 | 3.6 | 5.0 | 34.8 | 29.1 |
HAE | 2023-12-21 | 3.5 | 4.9 | 33.8 | 28.4 |
HAE Growth Metrics
- The 3 year cash and equivalents growth rate now stands at 53.23%.
- Its 3 year net income to common stockholders growth rate is now at -21.16%.
- Its 5 year net income to common stockholders growth rate is now at 391.33%.
The table below shows HAE's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 1,129.246 | 261.497 | 95.759 |
2022-09-30 | 1,083.714 | 259.515 | 86.047 |
2022-06-30 | 1,026.126 | 215.936 | 67.706 |
2022-03-31 | 993.196 | 172.263 | 43.375 |
2021-12-31 | 953.223 | 105.76 | 22.593 |
2021-09-30 | 933.825 | 109.618 | 31.243 |
HAE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HAE has a Quality Grade of C, ranking ahead of 50% of graded US stocks.
- HAE's asset turnover comes in at 0.569 -- ranking 76th of 186 Medical Equipment stocks.
- CRY, CTSO, and CSII are the stocks whose asset turnover ratios are most correlated with HAE.
The table below shows HAE's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-07-03 | 0.569 | 0.460 | 0.072 |
2021-04-03 | 0.581 | 0.457 | 0.090 |
2020-12-26 | 0.650 | 0.486 | 0.150 |
2020-09-26 | 0.674 | 0.485 | 0.151 |
2020-06-27 | 0.738 | 0.485 | 0.142 |
2020-03-28 | 0.798 | 0.490 | 0.116 |
HAE Price Target
For more insight on analysts targets of HAE, see our HAE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $79.25 | Average Broker Recommendation | 1.38 (Strong Buy) |
Haemonetics Corporation (HAE) Company Bio
Haemonetics designs, manufactures, and markets blood management solutions. The Company serves in three markets, such as manufacturers of plasma-derived pharmaceuticals, blood collectors, and hospitals. The company was founded in 1971 and is based in Braintree, Massachusetts.
Latest HAE News From Around the Web
Below are the latest news stories about HAEMONETICS CORP that investors may wish to consider to help them evaluate HAE as an investment opportunity.
Here's Why You Should Invest in Insulet (PODD) Stock for NowInvestors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position. |
Here's Why You Should Retain Illumina (ILMN) Stock for NowInvestors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position. |
National Vision (EYE) Store Openings Aid, Macro Issues StayIn terms of store expansion, National Vision (EYE) continues to see sizable new opportunities for many years to come. |
Reasons to Buy Prestige Consumer (PBH) Stock for NowInvestors remain optimistic about Prestige Consumer (PBH), backed by the robust strength of its consumer brands portfolio. |
Align Technology (ALGN) Up 30% YTD: Will the Rally Continue?Investors are optimistic about Align Technology (ALGN), driven by recent strategic alliance and geographic expansion. |
HAE Price Returns
1-mo | 4.74% |
3-mo | -12.07% |
6-mo | -15.87% |
1-year | -3.06% |
3-year | -33.48% |
5-year | -14.01% |
YTD | -11.37% |
2023 | 8.72% |
2022 | 48.28% |
2021 | -55.33% |
2020 | 3.35% |
2019 | 14.84% |
Continue Researching HAE
Want to do more research on Haemonetics Corp's stock and its price? Try the links below:Haemonetics Corp (HAE) Stock Price | Nasdaq
Haemonetics Corp (HAE) Stock Quote, History and News - Yahoo Finance
Haemonetics Corp (HAE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...